Press Releases

Media Inquiries - media@caredxinc.com

 
Press Releases
Date Title and Summary View
Jun 9, 2017 BRISBANE, Calif., June 09, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the first quarter ended March 31, 2017. "We are...
May 30, 2017 BRISBANE, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will highlight CareDx's Olerup pre-transplant diagnostics at the 31st European Immunogenet...
May 22, 2017 BRISBANE, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that, as expected, on May 22, 2017 it received a standard notification let...
May 22, 2017 BRISBANE, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported preliminary financial results for the first quarter ended March 31, 2017. ...
May 19, 2017 BRISBANE, Calif., May 19, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release preliminary financial results for the first quarter 2...
May 4, 2017 BRISBANE, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA) announces that Palmetto GBA has released a draft local coverage determination (LCD) for AlloSure. AlloSure is the first and only non-invasive test that uses donor derived cell free DNA as a biomarker to directly measure allograft injury and identify the probability of a...
Apr 28, 2017 BRISBANE, Calif., April 28, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA) and collaborators will present data highlighting the AlloSure test at the American Transplantation Congress (ATC) from April 29 - May 3, 2017 in Chicago. AlloSure is the first and only noninvasive test that uses donor-derived cell-free DNA (dd-cfDNA) as a biomarker to...
Apr 21, 2017 BRISBANE, Calif., April 21, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that, as expected, on April 19, 2017 it received a standard notification...
Apr 21, 2017 BRISBANE, Calif., April 21, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients, announces the appointment of Michael Bell as Chief Financial Officer joining CareDx ef...
Apr 21, 2017 BRISBANE, Calif., April 21, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the fourth quarter and year ended December 31, 2016...
Page:
1
... NextLast
= add release to Briefcase